{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:10:18Z","timestamp":1785777018325,"version":"3.56.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.semarthrit.2022.152136","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:12:42Z","timestamp":1668391962000},"page":"152136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0328-7062","authenticated-orcid":false,"given":"Sophie I.E.","family":"Liem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Neppelenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Fehres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie","family":"Wortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E.M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans U.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152136_bib0001","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","article-title":"Role of B cells in the pathogenesis of systemic sclerosis","volume":"38","author":"Sanges","year":"2017","journal-title":"La Revue Med Interne"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0005","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/eji.202048820","article-title":"Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases","volume":"50","author":"Reijm","year":"2020","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0008","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01451042","article-title":"How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?","volume":"17","author":"Meyer","year":"1998","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0011","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0012","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2010.08412.x","article-title":"Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters","volume":"152","author":"Toltl","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0014","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"10115","key":"10.1016\/j.semarthrit.2022.152136_bib0016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(17)31796-8","article-title":"Coeliac disease","volume":"391","author":"Lebwohl","year":"2018","journal-title":"Lancet"},{"issue":"10138","key":"10.1016\/j.semarthrit.2022.152136_bib0017","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"issue":"570","key":"10.1016\/j.semarthrit.2022.152136_bib0018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152136_bib0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0021","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0022","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"20","key":"10.1016\/j.semarthrit.2022.152136_bib0023","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J Biol Chem"},{"issue":"4739","key":"10.1016\/j.semarthrit.2022.152136_bib0024","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.3003910","article-title":"High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients","volume":"231","author":"Shero","year":"1986","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF00286991","article-title":"Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I","volume":"94","author":"Guldner","year":"1986","journal-title":"Chromosoma"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1172\/JCI112320","article-title":"Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies","volume":"77","author":"Earnshaw","year":"1986","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0027","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/art.1780330515","article-title":"The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies","volume":"33","author":"Hildebrandt","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI116343","article-title":"Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis","volume":"91","author":"Kuwana","year":"1993","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0029","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.7326\/0003-4819-119-10-199311150-00007","article-title":"Autoantibody reactive with RNA polymerase III in systemic sclerosis","volume":"119","author":"Okano","year":"1993","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.1780390712","article-title":"Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.86.1.237","article-title":"Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice","volume":"86","author":"Reuter","year":"1989","journal-title":"Proc Nat Acad Sci USA"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0032","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-1759(94)90261-5","article-title":"Screening for autoantibodies to the nucleolar U3- and Th (7-2) ribonucleoproteins in patients' sera using antisense riboprobes","volume":"169","author":"Verheijen","year":"1994","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0033","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.1780331007","article-title":"Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients","volume":"33","author":"D'Arpa","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0034","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/art.1780361013","article-title":"Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis","volume":"36","author":"Kuwana","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0035","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1165\/ajrcmb.22.3.3850","article-title":"B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis","volume":"22","author":"Rizou","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0036","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/intimm\/dxp008","article-title":"Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus","volume":"21","author":"Simon","year":"2009","journal-title":"Int Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0037","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0161-5890(91)90145-A","article-title":"An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients","volume":"28","author":"Piccinini","year":"1991","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0038","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.104.4.817","article-title":"Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen","volume":"104","author":"Earnshaw","year":"1987","journal-title":"J Cell Biol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0039","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/rheumatology\/34.5.407","article-title":"Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of cenp-b in patients with autoimmune disease","volume":"34","author":"Whyte","year":"1995","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0040","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3029","article-title":"Clinical and serological evaluation of a novel CENP-A peptide based ELISA","volume":"12","author":"Mahler","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"14","key":"10.1016\/j.semarthrit.2022.152136_bib0041","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1073\/pnas.84.14.4979","article-title":"Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B","volume":"84","author":"Earnshaw","year":"1987","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0042","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaut.2006.10.001","article-title":"Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies","volume":"27","author":"Akbarali","year":"2006","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0043","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2249.2000.01189.x","article-title":"Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3","volume":"120","author":"Muro","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0044","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s001090000128","article-title":"Fine-specificity of the anti-CENP-A B-cell autoimmune response","volume":"78","author":"Mahler","year":"2000","journal-title":"J Mol Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s001090100258","article-title":"A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1","volume":"79","author":"Mahler","year":"2001","journal-title":"J Mol Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0046","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/art.10521","article-title":"Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0047","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P","article-title":"Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes","volume":"42","author":"Kuwana","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0048","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00996355","article-title":"The specificity of disease-associated anti-fibrillarin autoantibodies compared with that of HgCl2-induced autoantibodies","volume":"20","author":"L\u00fcbben","year":"1994","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0049","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.181.3.1027","article-title":"Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes","volume":"181","author":"Kasturi","year":"1995","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4049\/jimmunol.154.2.961","article-title":"Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity","volume":"154","author":"Takeuchi","year":"1995","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0051","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/eci.11.26","article-title":"Deciphering the genetic background of systemic sclerosis","volume":"7","author":"Broen","year":"2011","journal-title":"Expert Rev Clinic Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0052","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2021-219884","article-title":"Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes","volume":"80","author":"Acosta-Herrera","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0053","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0054","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1046\/j.1365-2249.2002.01991.x","article-title":"Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations","volume":"130","author":"Van Eenennaam","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0055","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.autrev.2010.06.005","article-title":"Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?","volume":"9","author":"Mahler","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0056","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/1529-0131(200102)44:2<376::AID-ANR56>3.0.CO;2-2","article-title":"Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus","volume":"44","author":"Gussin","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0057","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/03009740600588376","article-title":"Anti-centromere antibodies in patients with systemic lupus erythematosus","volume":"35","author":"Respaldiza","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0058","first-page":"142","article-title":"Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis","volume":"27","author":"Russo","year":"2000","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0059","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/ar2958","article-title":"Anticentromere antibody positive Sj\u00f6gren's Syndrome: a retrospective descriptive analysis","volume":"12","author":"Bournia","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/annrheumdis-2020-218881","article-title":"Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling","volume":"80","author":"Kajio","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0061","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/acr.22859","article-title":"Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sj\u00f6gren's Syndrome: analysis of the Sj\u00f6gren's International Collaborative Clinical Alliance Cohort","volume":"68","author":"Baer","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"16","key":"10.1016\/j.semarthrit.2022.152136_bib0062","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0063","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","article-title":"The B cell response to citrullinated antigens in the development of rheumatoid arthritis","volume":"14","author":"Scherer","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0064","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0065","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0066","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0067","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0068","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/ard.52.8.586","article-title":"Anticentromere antibodies in subjects with no apparent connective tissue disease","volume":"52","author":"Lee","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0069","doi-asserted-by":"crossref","DOI":"10.1002\/art.41814","article-title":"Anti-centromere antibody levels and isotypes and the development of systemic sclerosis","author":"van Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0070","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0071","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/art.1780340111","article-title":"Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study","volume":"34","author":"Weiner","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0072","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/acr.22304","article-title":"Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity","volume":"66","author":"Valentini","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0073","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2-4","key":"10.1016\/j.semarthrit.2022.152136_bib0074","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/08830189509056709","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"V\u00e1zquez-Abad","year":"1995","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.61.2.121","article-title":"Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis","volume":"61","author":"Dick","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 76","key":"10.1016\/j.semarthrit.2022.152136_bib0076","first-page":"96","article-title":"Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study","volume":"31","author":"Heijnen","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0077","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000159","article-title":"Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis","volume":"2","author":"Meijs","year":"2016","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0078","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1038\/s41598-022-15062-4","article-title":"Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes","volume":"12","author":"Clark","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0079","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152136_bib0081","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152136_bib0082","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective european scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0083","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0084","article-title":"Association between centromere and topoisomerase specific immune responses and the degree of microangiopathy in systemic sclerosis","author":"van Leeuwen","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0086","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/ar628","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0087","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0088","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0089","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with Anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0090","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0091","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br J Dermatol"},{"issue":"10103","key":"10.1016\/j.semarthrit.2022.152136_bib0092","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0093","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000971","article-title":"Performance of anti-topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting","volume":"26","author":"Homer","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152052","article-title":"False positive anti-topoisomerase I (Scl-70) antibody results in clinical practice: a case series from a scleroderma referral center","volume":"56","author":"Lam","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0095","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/0961203319868531","article-title":"Autoantibodies in SLE: prediction and the p value matrix","volume":"28","author":"Choi","year":"2019","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0096","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/BOR.0000000000000200","article-title":"Update on the pathogenesis and treatment of the antiphospholipid syndrome","volume":"27","author":"Chighizola","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152136_bib0097","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sj\u00f6gren's syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0098","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0099","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.1780270201","article-title":"A long-term longitudinal study of anticentromere antibodies","volume":"27","author":"Tramposch","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/clin.1995.1038","article-title":"Longitudinal study of anticentromere and antitopoisomerase-I isotypes","volume":"74","author":"Vazquez-Abad","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0101","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","article-title":"Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis","volume":"43","author":"Kuwana","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0102","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/art.10977","article-title":"Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis","volume":"48","author":"Hu","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0103","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1346-8138.12030","article-title":"Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis","volume":"40","author":"Hasegawa","year":"2013","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0105","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0106","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B Cell responses: cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0107","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0108","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1002\/art.21232","article-title":"Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis","volume":"52","author":"Kuwana","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0109","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/rheumatology\/kep215","article-title":"A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis","volume":"48","author":"Nihtyanova","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0110","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67209","article-title":"Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model","volume":"10","author":"Fukasawa","year":"2021","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0111","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0112","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0113","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/jdv.12512","article-title":"Disappearance of circulating autoantibodies to RNA polymerase III in a patient with systemic sclerosis successfully treated with corticosteroid and methotrexate","volume":"29","author":"Tanahashi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152136_bib0114","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1093\/rheumatology\/keab257","article-title":"Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients","volume":"60","author":"Lima-J\u00fanior","year":"2021","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0115","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/art.21036","article-title":"Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis","volume":"52","author":"Farge","year":"2005","journal-title":"Arthritis Rheumatism"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0116","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0117","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/keq414","article-title":"Analysis of immune reconstitution after autologous CD34+ stem\/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells","volume":"50","author":"Tsukamoto","year":"2011","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0118","first-page":"451","article-title":"Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0119","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152136_bib0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2015.1069888","article-title":"Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?","volume":"44","author":"Moazedi-Fuerst","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0121","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0122","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0123","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0124","first-page":"2243","article-title":"Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice","volume":"34","author":"Hu","year":"2007","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0125","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1002\/art.30539","article-title":"Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling","volume":"63","author":"Yoshizaki","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0126","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219822","article-title":"X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc)","author":"Bergmann","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152136_bib0127","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/08916934.2016.1230848","article-title":"Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis","volume":"49","author":"Mehta","year":"2016","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1247\/csf.17.129","article-title":"An antigenic determinant on human centromere protein B (CENP-B) available for production of human-specific anticentromere antibodies in mouse","volume":"17","author":"Sugimoto","year":"1992","journal-title":"Cell Struct Funct"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.677970","article-title":"Transfer of PBMC from SSc patients induces autoantibodies and systemic inflammation in Rag2-\/-\/IL2rg-\/- Mice","volume":"12","author":"Yue","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/08916939109006746","article-title":"Self reactive repertoire of tight skin mouse: immunochemical and molecular characterization of anti-topoisomerase I autoantibodies","volume":"9","author":"Muryoi","year":"1991","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0131","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.175.4.1103","article-title":"Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes","volume":"175","author":"Muryoi","year":"1992","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0132","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4049\/jimmunol.175.4.2418","article-title":"Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma","volume":"175","author":"Gentiletti","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0133","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1172\/JCI116675","article-title":"Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse","volume":"92","author":"Shibata","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/cimm.1996.0017","article-title":"Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice","volume":"167","author":"Hatakeyama","year":"1996","journal-title":"Cell Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152136_bib0135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clim.2006.02.006","article-title":"Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)","volume":"120","author":"Servettaz","year":"2006","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152136_bib0136","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","article-title":"CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma","volume":"172","author":"Yoshizaki","year":"2008","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0137","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.4049\/jimmunol.158.7.3521","article-title":"The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties","volume":"158","author":"Pollard","year":"1997","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0138","first-page":"470","article-title":"Anti-fibrillarin autoantibodies in mercury-treated mice","volume":"78","author":"Hultman","year":"1989","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0139","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.clinthera.2016.02.029","article-title":"The alarmin properties of DNA and DNA-associated nuclear proteins","volume":"38","author":"Magna","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.cdd.4402239","article-title":"Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis","volume":"15","author":"Schiller","year":"2008","journal-title":"Cell Death Different"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152136_bib0141","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1002\/art.22972","article-title":"The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells","volume":"56","author":"Robitaille","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152136_bib0142","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"Henault","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0143","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/jmp2040024","article-title":"Clinical and molecular features of anti-CENP-B autoantibodies","volume":"2","author":"Prasad","year":"2021","journal-title":"J Mol Pathol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0144","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","article-title":"The role of defective clearance of apoptotic cells in systemic autoimmunity","volume":"6","author":"Mu\u00f1oz","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0145","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/art.20515","article-title":"Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis","volume":"50","author":"Henault","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0146","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-019-1931-x","article-title":"Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?","volume":"21","author":"Corallo","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152136_bib0147","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/art.33484","article-title":"Heparin inhibits the interaction of DNA topoisomerase I\/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts","volume":"64","author":"Arcand","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0148","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152136_bib0149","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","article-title":"Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts","volume":"20","author":"Raschi","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0151","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152136_bib0152","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4049\/jimmunol.117.1.253","article-title":"Appearance of IgG (Fc) receptor (s) on cultured human fibroblasts infected with human cytomegalovirus","volume":"117","author":"Rahman","year":"1976","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0153","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0154","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0155","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05542-1","article-title":"Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis","author":"Borrirukwisitsak","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152136_bib0156","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1172\/JCI65292","article-title":"Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis","volume":"123","author":"Roth","year":"2013","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152136_bib0157","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152136_bib0158","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-022-08930-4","article-title":"Systemic sclerosis association with malignancy","author":"Lepri","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152136_bib0159","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3899\/jrheum.160106","article-title":"Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis","volume":"43","author":"Nandiwada","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:06Z","timestamp":1758733746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":159,"alternative-id":["S0049017222001871"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152136","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152136"}}